Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441178 | 0.84 | KMT2A (0.35) | KMT2AMAPK1S1PR1S1PR3P2RX3 | |
| SCHEMBL17823946 | 0.84 | KMT2A (0.35) | KMT2AMAPK1S1PR1S1PR3P2RX3 | |
| Hydrochloric Acid SCHEMBL31482133 | 0.82 | KMT2A (0.34) | KMT2AMAPK1S1PR1S1PR3P2RX3 | |
| Hydrochloric Acid SCHEMBL17824033 | 0.82 | KMT2A (0.34) | KMT2AMAPK1S1PR1S1PR3P2RX3 | |
| SCHEMBL21725522 | 0.81 | KMT2A (0.33) | KMT2AMAPK1S1PR1S1PR3P2RX3 | |
| SCHEMBL2609312 | 0.78 | LMNA (0.44) | KMT2AMAPK1S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL2737358 | 0.78 | AGBL2 (0.32) | JAK2 | |
| SCHEMBL22871210 | 0.78 | KMT2A (0.32) | KMT2AMAPK1S1PR1S1PR3P2RX3 | |
| SCHEMBL2738316 | 0.77 | AGBL2 (0.42) | S1PR1S1PR3 | |
| SCHEMBL12248259 | 0.77 | CCR1 (0.35) | KMT2AMAPK1S1PR1S1PR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3611165-B1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3636636-B1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUI CHEMICALS AGRO INC (JP) | 2022-07-06 | — | — | EP | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | KMT2A 4819/4885MAPK1 2196/4885S1PR1 255/4885 |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | KMT2A 4588/4885MAPK1 2393/4885S1PR1 173/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | KMT2A 1341/4885MAPK1 3270/4885S1PR1 1233/4885 |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | KMT2A 1197/4885MAPK1 1919/4885S1PR1 487/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | KMT2A 1341/4885MAPK1 3270/4885S1PR1 1233/4885 |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | KMT2A 4588/4885MAPK1 2393/4885S1PR1 173/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | KMT2A 4819/4885MAPK1 2196/4885S1PR1 255/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | KMT2A 1341/4885MAPK1 3270/4885S1PR1 1233/4885 |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | KMT2A 4819/4885MAPK1 2196/4885S1PR1 255/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | KMT2A 1341/4885MAPK1 3270/4885S1PR1 1233/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | KMT2A 1341/4885MAPK1 3270/4885S1PR1 1233/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | KMT2A 1341/4885MAPK1 3270/4885S1PR1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.